Neurology and Neurosurgery

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Craig Chepke, MD, FAPA From a women's mental health pre-conference to new mechanisms of action coming into psychiatry for the first time in decades, there’s a lot to look forward to at this year’s meeting. Join Dr. Mary Katherine Cheeley as she gets more highlights from Dr. Craig Chepke, Medical Director of Excel Psychiatric Associates and Psych Congress 2023 Scientific Advisor.

Host: Andrew Wilner, MD, FACP, FAAN Guest: Eoin Flanagan, MB, BCh For the first time since 2008, the International Advisory Committee on Clinical Trials in Multiple Sclerosis have made updates to their diagnostic guidelines for patients with suspected multiple sclerosis (MS). Joining Dr. Andrew Wilner to discuss these key updates is Dr. Eoin Flanagan, the Chair of the Division of Multiple Sclerosis and Autoimmune Neurology at the Mayo Clinic in Rochester, Minnesota.

Host: Atul Malhotra, MD Host: Neomi Shah, MD, MPH, MSc This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Atul Malhotra, MD Host: Neomi Shah, MD, MPH, MSc This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Atul Malhotra, MD Host: Christina Finch, MD This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Atul Malhotra, MD This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Neomi Shah, MD, MPH, MSc This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Christina Finch, MD This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Neomi Shah, MD, MPH, MSc This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Christina Finch, MD This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Christina Finch, MD This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.

Host: Andrew Wilner, MD, FACP, FAAN Guest: John Corboy, MD, MA Disease-modifying therapies (DMTs) reduce disease activity and slow the progression of disability in multiple sclerosis. But there were some challenges that came out of this recent study. To discuss the findings from this trial, Dr. Andrew Wilner is joined by Dr. John Corboy, Professor of Neurology and the Director of the Rocky Mountain MS Center at the University of Colorado.

Guest: Sergio Baranzini, PhD A recent study was designed by the International Multiple Sclerosis Genetics Consortium with the goal in mind to find out whether the severity of multiple sclerosis (MS) could be influenced by genetics. Dive in with Dr. Sergio Baranzini, Distinguished Professor of Neurology at the University of California San Fransico and Co-Senior Author of the study.

Host: Craig I. Coleman, PharmD, FASHP Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Craig I. Coleman, PharmD, FASHP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Craig I. Coleman, PharmD, FASHP The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

Host: Deborah Siegal, MD, MSc, FRCPC The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.